| ORIGINAL ARTICLE |
|
| Year : 2015 | Volume
: 52
| Issue : 5 | Page : 12-16 |
A meta-analysis of erlotinib versus docetaxel for advanced nonsmall-cell lung cancer with poor prognosis
W Xu1, C Jin1, X Dai2, X Lv3
1 Department of General Surgery, Sanmen Hospital of Traditional Chinese Medicine, Sanmen 317100, India
2 The Quality Management Office, The Second Affiliated Hospital of Zhejiang University, Hangzhou 310009, China
3 Department of Thoracic Surgery, The First Affiliated Hospital of Zhejiang University, Hangzhou 310009, China
Correspondence Address:
X Lv
Department of Thoracic Surgery, The First Affiliated Hospital of Zhejiang University, Hangzhou 310009
China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0019-509X.168957
Background: The extent of the benefit of erlotinib in the treatment of advanced nonsmall-cell lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta-analysis was performed to compare the efficacy of erlotinib with docetaxel for different patients with advanced NSCLC. Materials and Methods: We searched Cochrane Library, PubMed, CNKI, and identified 23 randomized controlled clinical trials from 2008 to 2015. According to our further full-text screening, 6 clinical trials were included in the final meta-analysis. Results: Six papers were included in this study. The progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and toxicity were included in our outcomes. The pooled hazard ratio (HR) of PFS was 1.57 (95% confidential index [CI] = 1.47–1.69). The pooled HR of OS was 1.66 (95% CI = 1.43–1.92). The pooled risk ratio of ORR was 0.56 (95% CI = 0.35–0.91). The toxicity analysis showed odds ratio = 1.79 (95% CI = 1.20–2.69). Conclusions: In terms of PFS, OS, and toxicity the effect of erlotinib in the treatment of advanced NSCLC patients is superior to docetaxel.
[FULL TEXT] [PDF]*
|
